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patients at risk for COPD (aged 45 ≤ years ≤ 85, ≥15 pack years) were included. Lung 
function (FEV1 and FEV6) was measured by copd-6 (mini-spirometer, Vitalograph), 
followed by ordinary spirometry (COPD diagnosis FEV1/FVC post bronchodilation 
ratio <70). Time consumed was recorded and costs calculated (national average nurse 
wage). Univariate logistic regression and receiver operating characteristic (ROC) 
curves were utilized. RESULTS: In all, 305 patients (21 centers in Sweden), females 
57%, mean (standard deviation, SD) age 61.2 (8.4) years, FEV1/FVC 75.3 (10.2), 
pack years 30.3 (11.5) were included. COPD was diagnosed in 83 patients (27.2%). 
Copd-6 screening signiﬁ cantly predicted COPD by FEV1/FEV6 ratio. Patients with 
COPD had a mean (SD) FEV1/FEV6 of 69.0 (9.1), patients without COPD 77.7 (9.6). 
Sensitivity and speciﬁ city at a FEV1/FEV6 cut-off of 73.0 was 73.5% and 79.7%, 
respectively; area under the ROC curve was 0.800. Cost of one copd-6 measurement 
(~4 minutes) was SEK 19 (≈c2), while the cost for an ordinary spirometry (~33 
minutes) was SEK 147 (≈c15). Without copd-6 pre-screening the cost of detecting one 
COPD patient based on age and pack years was SEK 542 (≈c54). Use of copd-6 
reduces the cost to SEK 283 (≈c28), but also results in an 8.4% lower COPD detection 
rate due to copd-6 sensitivity limitations. CONCLUSIONS: Pre-screening with the 
copd-6 mini-spirometer to select patients (≥45 years; ≥15 pack years) for ordinary 
spirometry increased the frequency of detected COPD diagnoses from 27.2% to 
73.5%. Although copd-6 sensitivity and speciﬁ city could be improved, its use in 
primary care may reduce the costs of detecting COPD patients.
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OBJECTIVES: To estimates cost and effectiveness of beclomethasone/formoterol 
extraﬁ ne, ﬂ uticasone/salmeterol and budesodine/formoterol in the treatment of moder-
ate to severe persistent asthma in Spain. METHODS: A Markov model was developed 
to represent the transition of a cohort of patients with moderate to severe persistent 
asthma through different health states: patients free of symptoms, patients with exac-
erbations and patients without exacerbations. Efﬁ cacy data was obtained from obser-
vational studies. Deterministic results were estimated and a probabilistic sensitivity 
analysis was conducted using statistical distributions in order to capture parameter 
uncertainty in the decision model. Treatment costs were obtained from literature 
review and a panel of clinical experts. Costs were referred to year 2009 and a time 
horizon of 12 weeks was chosen. Results were presented as expected cost per QALY 
and represented in cost-effectiveness acceptability curves (CEACs). RESULTS: In the 
deterministic analysis, the expected cost per patient was greater in the ﬂ uticasone/
salmeterol cohort (c333) and the budesodine/formoterol cohort (c300) in comparison 
with the beclomethasone/formoterol cohort (c292). The estimated effectiveness was 
the same in the three cohorts. In the probabilistic analysis CEACs showed that the 
probability that the treatment with beclomethasone/formoterol was more cost-effec-
tive than the treatment with ﬂ uticasone/salmeterol and budesodine/formoterol using 
alternative values for the maximum value that the health service would be willing to 
pay for an additional QALY gained was greater in the beclomethasone/formoterol 
cohort. CONCLUSIONS: When beclomethasone/formoterol extraﬁ ne has been com-
pared to ﬂ uticasone/salmeterol and budesodine/formoterol we may conclude that the 
ﬁ rst one is a dominant strategy. Results from probabilistic sensibility analysis show 
that the choice of optimal strategy is independent on the maximum that the health 
service is prepared to pay per additional QALY gained because beclomethasone/for-
moterol extraﬁ ne has a greater probability of being cost-effective for all threshold 
values. 
RESPIRATORY-RELATED DISORDERS – Patient-Reported Outcomes 
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OBJECTIVES: Medication adherence and health-related quality of life (HRQoL) are 
important factors in determining success of drug treatments; although both have been 
studied intensively, limited data is available on the association between these factors. 
This study aimed: 1) to assess the relationship between adherence and HRQoL in 
COPD patients using generic and disease speciﬁ c instruments; and 2) to evaluate the 
association between adherence and answers of SGRQ part 2-section 5 referring to 
medication use. METHODS: The cross-sectional study included a post-bronchodilator 
spirometry and completion of a self reported postal questionnaire. Information on 
adherence (4-item Morisky Medication Adherence Scale) and HRQoL (generic: 
EuroQol—EQ-5D, disease speciﬁ c: St. George’s Respiratory Questionnaire—SGRQ) 
were obtained. Multiple linear regression model was used to analyze the association 
between HRQoL as dependent variable and disease severity (FEV1), age and adherence 
as independent variables. Differences in answers of SGRQ part 2-section 5 between 
adherence stages were analyzed with Pearson Chi-square test. RESULTS: A total of 
227 patients were included at baseline, 170 of them completed the study. The mean 
age was 63.83 (SD = 11.24) years, there were slightly more female patients (58%). a 
total of 32% (n = 55) of the participants reported themselves as high adherent, 26% 
(n = 44) were medium, and 42% (n = 71) were low adherent. The mean EQ-5D score 
was 0.55 (SD = 0.21) and the mean SGRQ total score was 56.22% (SD = 16.19). 
HRQoL assessed with EQ-5D and SGRQ were neither signiﬁ cantly related to medica-
tion adherence. Both generic and disease-speciﬁ c HRQoL were associated with age 
and disease severity. We found signiﬁ cant association between the number of the 
positive answers’ of SGRQ part 2-section 5 and adherence rate (Chi-square = 30.64 
p = 0.000). CONCLUSIONS: The study showed no signiﬁ cant relationship between 
adherence to medication and any HRQoL domain. Our results suggest that, SGRQ 
part 2-section 5 could be suitable to estimate adherence in patients with COPD in 
clinical practice.
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OBJECTIVES: It is hypothesised that patient satisfaction with the features of an 
asthma inhaler directly inﬂ uences compliance behaviour of asthma patients. This study 
investigated the relationship between physician-reported compliance of 1400 asthma 
patients with the degree of patient-reported satisfaction with their inhaler. METHODS: 
Data were drawn from the Adelphi Disease Speciﬁ c Programme (DSP) in Asthma, a 
cross-sectional study of consulting patients undertaken in 2009. Data were collected 
from physicians for each patient and collected directly from consenting patients. Key 
factors analyzed were physician-reported perceptions of patient compliance on a 1–5 
scale (where 1 is ‘not at all compliant’ and 5 is ‘fully compliant’) and data for patient-
reported satisfaction with their inhaler including speciﬁ c device features associated with 
convenience, dosing and inhaler mechanism. The results were tested against potential 
confounders including age, gender, ethnicity and current asthma severity, to ensure the 
relationship effect between compliance and satisfaction was distinct. RESULTS: There 
was a signiﬁ cant relationship between the physician-reported level of compliance and 
patient-reported satisfaction with their inhaler device. The investigators observed that 
a better perceived level of compliance was directly associated with a higher level of 
inhaler satisfaction (P < 0.001). Those inhaler features associated with convenience: 
“built to last/will not break easily”; “easy to hold and carry,” “instructions are simple 
and easy to follow,” and “no need to put the drug into the inhaler before use” 
accounted for four of the top ﬁ ve drivers of overall satisfaction. CONCLUSIONS: 
Patient satisfaction with features of their inhaler is an important factor in promoting 
patient compliance. If physicians made particular effort to select an inhaler that satisﬁ es 
the patient, including attention to features associated with convenience, patient compli-
ance with their asthma treatment would be expected to improve.
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OBJECTIVES: This study assesses the impact of high prevalence comorbidities 
reported by persons with diagnosed COPD on their health related quality of life 
(HRQoL). The focus is on (1) the quantitative impact of comorbidities on SF-6D utility 
scores, and (2) the relative impact of symptomatic vs. non-symptomatic comorbid 
disease states. METHODS: The study is based on data from the internet based 2008 
National Health and Wellness Survey (NHWS) undertaken in the UK, France, Spain, 
Germany, and Italy. The study identiﬁ ed 3103 persons with diagnosed COPD together 
with the nine most frequently diagnosed comorbidities: pain, high blood pressure, 
anxiety, high cholesterol, heartburn, insomnia, depression, migraine, and arthritis. 
High blood pressure and high cholesterol are considered non-symptomatic comorbidi-
ties. The impact of these comorbidities on the SF-6D utility scores (range 0–1) is 
estimated via an ordinary least squares regression model. All comorbidities enter as 
categorical variables. The model includes a range of variables which have been shown 
in previous studies to impact HRQoL. These include: sociodemographic factors, health 
risk behaviors (BMI, alcohol use, smoking), and a series of country dummy variables 
(Germany as reference category). RESULTS: The model demonstrates that for symp-
tomatic comorbidites the impact on utility scores is substantial. All symptomatic 
comorbidities are signiﬁ cant. Depression followed by pain experienced in the past 6 
months have the greatest deﬁ cit impact (respectively −0.060; 95% CI −0.071 to −0.050 
and −0.055; 95% CI −0.064 to −0.045). High blood pressure and high cholesterol are 
not signiﬁ cant. CONCLUSIONS: Claims for the negative impact of COPD on HRQoL 
should be seen in the context of a cluster of comorbid disease states; in particular the 
high prevalence disease states such a pain, anxiety and depression.
